Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000708 · ClinicalTrials.gov registry record · NA

Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis

A NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
NA
Development phase
120
Enrollment target

NCT00000708: Completed NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT00000708 is a NA study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 120 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000708, a NA study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
NA
Development phase
120 participants
Enrollment target

Study Summary

To compare the safety and effectiveness of fluconazole (FCZ) and amphotericin B (AMB), alone or in combination with flucytosine (FLC), as treatment for acute cryptococcal meningitis in patients who have not been treated previously or who have relapsed after a previous successful treatment. Cryptococcal meningitis is an important cause of disease and death among patients with AIDS. Usually AMB is given either alone or with FLC to patients with this infection, but these treatments are not always effective and both have toxic effects. Animal studies and preliminary studies in humans show that FCZ is active in cryptococcal meningitis and suggest that it may be less toxic than either AMB or FLC.

Interventions

  • DRUG Fluconazole
  • DRUG Amphotericin B
  • DRUG Flucytosine

Trial Details

FieldValue
Enrollment Target 120 participants
Phase NA

What the finished NCT00000708 record still lists

NCT00000708 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).

The record links to 0 conditions, and to 3 interventions - of which Fluconazole is the first listed.

NCT00000708 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00000708 about?

NCT00000708 is a clinical study titled "Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis". To compare the safety and effectiveness of fluconazole (FCZ) and amphotericin B (AMB), alone or in combination with flucytosine (FLC), as treatment for acute cryptococcal meningitis in patients who have not been treated previously or who have relapsed after a previous successful treatment. Cryptoco...

What is the current status of trial NCT00000708?

This trial is currently completed. It is a NA study. The enrollment target is 120 participants.

What interventions are being tested in trial NCT00000708?

The interventions under investigation include: Fluconazole (DRUG), Amphotericin B (DRUG), Flucytosine (DRUG).

Who is sponsoring clinical trial NCT00000708?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00000708's enrollment target sits among peer trials

120 762nd of 2000 higher than 1,198 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174108 · 120 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

  • NCT01627301 · 120 participants · NA

    Sympathetic Overactivity in Post-traumatic Stress Disorder

  • NCT02025023 · 120 participants · Phase 3

    Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

  • NCT02128906 · 120 participants · Phase 2

    Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Source: ClinicalTrials.gov NCT00000708, the US trial registry maintained by the National Library of Medicine. NCT00000708 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.